BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Meetings conducted with Institutional Investors/Research Analysts.01-12-2022
01-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please note that CRISIL Ratings ('CRISIL') has reviewed the ratings on bank facilities of the Company. The rating letter received from CRISIL is attached as Annexure. The above information will also be available on the website of the Company at www.biocon.com.01-12-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Meetings conducted with Institutional Investors/Research Analysts.01-12-2022
Biocon subsidiary acquires Viatris pharma for $3 billion
Biocon Limited has announced the acquisition of Viatris by its biosimilar producing arm Biocon Biologics. The deal has been completed at $3 billion30-11-2022
Buzzing Stocks | Biocon, Inox Green Energy, IDFC and others in news today
Stocks to Watch: Check out the companies making headlines before the opening bell.30-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This disclosure is made in continuation to the disclosures made by the Company under Regulation 30 of SEBI LODR dated February 27, 2022, the quarterly press releases dated April 28, 2022, July 27, 2022, November 14, 2022 & the presentation with regard to the Earnings Call dated November 15, 2022. We hereby inform you that, Biocon Biologics Limited ('BBL') and its subsidiary, has today, i.e. on 29, November, 2022 completed the acquisition of the biosimilars businesses / assets of Viatris Inc. through: (i) Purchase of 100% stake in Biosimilar NewCo Limited ('BNCL'), a company incorporated in the United Kingdom; and (ii) Subscription, to 100% stake in Biosimilar Collaborations Ireland Limited ('BCIL'), a company incorporated in Ireland. Pursuant to such acquisitions, BNCL and BCIL have become step-down subsidiaries of BBL and indirect subsidiaries of Biocon Limited. A press release titled 'Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business ' is enclosed.29-11-2022
BIOCON LTD. - 532523 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').
In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended September 30, 2022, drawn in accordance with applicable accounting standard. The above information will also be available on the website of the Company at www.biocon.com.28-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Acquisition
This is with reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited (BBL), subsidiary of Biocon Limited and in continuation to our letter dated November 17, 2022, please be informed that BBL has allotted equity shares to Biocon Limited for an amount of Rs. 2,205.63 crores(~US$ 270 Million) on November 23, 2022.24-11-2022
Hold Biocon; target of Rs 290: ICICI Direct
ICICI Direct recommended hold rating on Biocon with a target price of Rs 290 in its research report dated November 15, 2022.24-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sir/Madam, Please find enclosed the press release titled 'Biocon Limited enters into a commercialization agreement with Zentiva in Europe' The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully,23-11-2022